Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic Review and Meta-Analysis
Joint Authors
Fan, Lai lai
Xie, Cheng Peng
Wu, Yi Ming
Gu, Xi jie
Chen, Ying he
Wang, Yi jun
Source
Issue
Vol. 2019, Issue 2019 (31 Dec. 2019), pp.1-15, 15 p.
Publisher
Hindawi Publishing Corporation
Publication Date
2019-04-03
Country of Publication
Egypt
No. of Pages
15
Main Subjects
Abstract EN
Background.
Prostate cancer (PCa) is the ninth most common cause of cancer death globally.
Many studies have investigated aspirin exposure and mortality risk among PCa patients, returning inconsistent results.
We conducted a comprehensive meta-analysis to explore the association between aspirin exposure and mortality risk among PCa patients and to investigate potential dose/duration/frequency-response relationships.
Methods and Results.
Studies published from 1980 to 2018 of PubMed and EMBASE databases were searched.
We included 14 studies with 110,000 participants.
Multivariate-adjusted odds ratios (ORs) were pooled using random-effect models.
Potential dose/duration/frequency-response relationships were evaluated for aspirin exposure and prostate cancer-specific mortality (PCSM) risk.
We did not detect an association between the highest aspirin exposure and mortality risk (PCSM of prediagnostic aspirin exposure, OR: 0.96, 95% confidence interval [CI]: 0.87-1.
07, I2 = 0%; PCSM of postdiagnostic aspirin exposure, OR:0.92, 95% CI: 0.77-1.10, I2 = 56.9%; all-cause mortality [ACM] of prediagnostic aspirin exposure, OR: 0.96, 95% CI: 0.88-1.04, I2 = 9.4%; ACM of postdiagnostic aspirin exposure, OR: 0.95, 95% CI: 0.73-1.23, I2 = 88.9%).
There was no significant dose/frequency-response association observed for aspirin exposure and PCSM risk.
On duration-response analysis, we found that short-term postdiagnostic aspirin exposure (shorter than 2.5 years) increased the risk of PCSM.
Conclusions.
Our meta-analysis suggests that there is no association between aspirin exposure and PCSM risk.
Nor is there an association between the highest aspirin exposure and ACM risk among PCa patients.
More studies are needed for a further dose/duration/frequency-response meta-analysis.
American Psychological Association (APA)
Fan, Lai lai& Xie, Cheng Peng& Wu, Yi Ming& Gu, Xi jie& Chen, Ying he& Wang, Yi jun. 2019. Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic Review and Meta-Analysis. BioMed Research International،Vol. 2019, no. 2019, pp.1-15.
https://search.emarefa.net/detail/BIM-1128513
Modern Language Association (MLA)
Fan, Lai lai…[et al.]. Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic Review and Meta-Analysis. BioMed Research International No. 2019 (2019), pp.1-15.
https://search.emarefa.net/detail/BIM-1128513
American Medical Association (AMA)
Fan, Lai lai& Xie, Cheng Peng& Wu, Yi Ming& Gu, Xi jie& Chen, Ying he& Wang, Yi jun. Aspirin Exposure and Mortality Risk among Prostate Cancer Patients: A Systematic Review and Meta-Analysis. BioMed Research International. 2019. Vol. 2019, no. 2019, pp.1-15.
https://search.emarefa.net/detail/BIM-1128513
Data Type
Journal Articles
Language
English
Notes
Includes bibliographical references
Record ID
BIM-1128513